![WomanWalkingE.jpg](https://static.wixstatic.com/media/76c860_59e3d77d939b4755a144f41880dd0ff5~mv2.jpg/v1/fill/w_147,h_53,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/76c860_59e3d77d939b4755a144f41880dd0ff5~mv2.jpg)
VT-X7
VT-X7
Osteal Therapeutics'® lead therapeutic candidate, VT-X7, is drug-device combination that delivers high concentrations of vancomycin and tobramycin, well-established antibiotic drugs, directly to the infected joint space. When used as part of a two-stage exchange arthroplasty procedure, VT-X7 has the potential to significantly lower treatment time and improve success rates.
VT-X7 is not approved by the FDA.
![implants and vials.png](https://static.wixstatic.com/media/1b555c_fe2ebc35c0494b539a0e7f62612f8768~mv2.png/v1/fill/w_419,h_287,al_c,lg_1,q_95,enc_auto/implants%20and%20vials.png)
Expected Advantages of VT-X7
-
Antibiotic concentrations at the infection site sufficient to penetrate biofilm
-
Effective against gram-negative and gram-positive organisms
-
Low antibiotic serum concentrations
-
Infection is treated and patient receives new revision prothesis in 7 days
-
Durable results: >90% of patients are infection free at 1 year post treatment
![](https://static.wixstatic.com/media/76c860_4db4c1cd9f164de49d0dbcc06ebdb721~mv2.jpg/v1/fill/w_55,h_64,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/76c860_4db4c1cd9f164de49d0dbcc06ebdb721~mv2.jpg)
![VT-X7 treatment graphic2.jpg](https://static.wixstatic.com/media/76c860_db537ba0dd5b459fb61f9398f21168d4~mv2.jpg/v1/fill/w_142,h_84,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/VT-X7%20treatment%20graphic2.jpg)
How VT-X7
Works
![](https://static.wixstatic.com/media/76c860_cea67d37a5294093bd763178707b0c33~mv2.png/v1/fill/w_184,h_209,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_auto/76c860_cea67d37a5294093bd763178707b0c33~mv2.png)
After removing the infected joint prosthesis, bone and soft tissue, the surgeon places a VT-X7 spacer and fluid management dressing, connecting them to an irrigation pump.
1
Place VT-X7 spacer
![VT-X7 antibiotics.png](https://static.wixstatic.com/media/1b555c_5ec0a2a2c9954a2288efd3bd048f0e14~mv2.png/v1/fill/w_187,h_162,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_auto/VT-X7%20antibiotics.png)
2
Over the course of one week in the hospital, more than 150 cycles of VT-X7 antibiotics are administered to the joint space through the VT-X7 spacer, allowed to penetrate and then withdrawn prior to initiation of the next cycle.
150+ cycles of VT-X7
3
After 7 days of therapy, the VT-X7 spacer is removed and replaced with a permanent joint prosthesis, and the patient proceeds to post-surgical physical therapy.
days of therapy
Successful Phase 2 Results
Osteal Therapeutics conducted a Phase 2 prospective, single-arm, clinical trial for the treatment of patients with infected hip and knee prostheses at 4 U.S. centers. In the trial all subjects received new revision joint prostheses after 7 days of therapy and a clinically and statistically significant percentage of subjects were infection free at 12 weeks and 1 year.